Your browser doesn't support javascript.
loading
Characterization of novel CTNNB1 mutation in Craniopharyngioma by whole-genome sequencing.
He, Juan; Zeng, Zhen; Wang, Yuelong; Deng, Jiaojiao; Tang, Xin; Liu, Fujun; Huang, Jianhan; Chen, Hongxu; Liang, Ruichao; Zan, Xin; Liu, Zhiyong; Tong, Aiping; Guo, Gang; Xu, Jianguo; Zhu, Xiaofeng; Zhou, Liangxue; Peng, Yong.
Afiliação
  • He J; Laboratory of Molecular Oncology, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Zeng Z; Laboratory of Molecular Oncology, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Wang Y; Key Laboratory of Bio-Resource and Eco-Environment of Ministry of Education, College of Life Sciences, Sichuan University, Chengdu, 610064, China.
  • Deng J; Laboratory of Molecular Oncology, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Tang X; Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Liu F; Department of Neurosurgery, Huashan Hospital, Fudan University, Shanghai, 20040, China.
  • Huang J; Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Chen H; Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Liang R; Laboratory of Molecular Oncology, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Zan X; Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Liu Z; Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Tong A; Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Guo G; Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Xu J; Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Zhu X; Laboratory of Molecular Oncology, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Zhou L; Laboratory of Molecular Oncology, Frontiers Science Center for Disease-related Molecular Network, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.
  • Peng Y; Department of Neurosurgery, West China Hospital, Sichuan University, Chengdu, 610041, China.
Mol Cancer ; 20(1): 168, 2021 12 18.
Article em En | MEDLINE | ID: mdl-34922552
ABSTRACT

BACKGROUND:

Craniopharyngioma (CP) is rare histologically benign but clinically challenging tumor because of its intimate relationship with the critical structure in the central brain. CP can be divided into two major histologic subtypes adamantinomatous-type CP (ACP) and papillary-type CP (PCP). Although some genetic aberrations for both categories have been revealed in previous studies, the complete spectrum of genetic changes of this tumor remains unknown.

METHODS:

In this study, we conducted whole genome sequencing (WGS) on twenty-six CPs including 16 ACPs and 10 PCPs together with their matched blood samples. Somatic variants (SNVs, InDels, SVs and CNVs) were identified and mutational signatures were characterized for each patient. We investigated the impact of a novel CTNNB1 mutant on its protein stability, ubiquitination and Wnt pathway activity. Cell proliferation ability of the CTNNB1 mutant in ACP primary cells was additionally analyzed by CCK8 and colony formation assays.

RESULTS:

We found that CPs had showed less complexity with fewer somatic mutations compared with malignant tumors. Moreover, mutations in CTNNB1 (68.75% of ACP) and BRAF V600E (70.00% of PCP) are mutually exclusive in ACP and PCP, consolidating that the driving roles of these two genes in ACP and PCP, respectively. A novel mutation in the exon 3 of CTNNB1 which compromised both a transversion and in-frame deletion was identified in ACP. This mutation was experimentally validated to confer ß-catenin increased stability by inhibiting its ubiquitination, thus activating Wnt-signaling pathway and promoting cell proliferation.

CONCLUSIONS:

Whole genome landscape for CP was revealed by WGS analysis, and a novel mutation in the exon 3 of CTNNB1 was identified. This novel mutation activates Wnt-signaling pathway through increasing the stability of ß-catenin. Our findings provided us with more comprehensive insight into the spectrum of genetic alterations in CP.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Hipofisárias / Craniofaringioma / Beta Catenina / Mutação Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Hipofisárias / Craniofaringioma / Beta Catenina / Mutação Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article